Is BPC-157 legal in the US?
The short answer
BPC-157 is not an FDA-approved drug and is not on the 503A Bulks List as of 2026-07-28. On 2026-07-23, FDA's Pharmacy Compounding Advisory Committee voted to recommend adding it — but that vote is advisory. FDA must still complete rulemaking before anything changes.
The July 23-24, 2026 vote
Caveat on this number: FDA took separate votes on BPC-157 free base and BPC-157 acetate; both were reported as 8-6. Official minutes were not published as of the status date.
What FDA actually evaluated
FDA assessed BPC-157 for one thing: ulcerative colitis.
FDA did not evaluate BPC-157 for injury repair, tendon or ligament healing, post-surgical recovery, Crohn's disease, celiac disease or tendonitis — the uses that drive most consumer demand.
Full regulatory status
| FDA-approved drug? | No FDA-approved drug product contains BPC-157 free base or BPC-157 acetate. |
|---|---|
| Indication FDA reviewed | Ulcerative colitis |
| PCAC recommendation | Recommended for the 503A Bulks List (advisory only) |
| FDA reviewers' position | Do not add to the 503A Bulks List. |
| Category 2 status | Previously in FDA's interim Category 2 (significant safety risk). Moved to the “nominated but withdrawn” table after the nomination was withdrawn in April 2026. Removal from Category 2 did not authorize compounding and did not move it to Category 1. |
| 503A Bulks List today | Not on the 503A Bulks List. A PCAC recommendation is advisory only — FDA must complete rulemaking before 21 CFR 216.23 changes. |
| 503B status | Not on the final 503B Bulks List, and not in FDA's published interim 503B categories. |
| Prescription status | No FDA-approved US status. Not an approved prescription or OTC drug. “Research use only” is a seller label, not authorization to administer to patients. |
| Next federal event | Possible FDA notice-and-comment rulemaking. No BPC-157 rulemaking date has been announced. |
If you compete in sport
Prohibited at all times, in and out of competition. USADA identifies BPC-157 by name as a prohibited substance.
Why FDA's own reviewers recommended against it
- Inconsistent identity and nomenclature across the nomination
- Inadequate controls for peptide-related impurities, aggregates, microbial contamination and endotoxin
- Immunogenicity concerns
- Inadequate nonclinical toxicology
- Very limited, short-duration human safety evidence
- Insufficient efficacy evidence for the nominated route and use
- FDA-approved ulcerative colitis treatments already available
What you can actually do today
You can discuss FDA-approved ulcerative colitis treatments with a licensed clinician. The July vote did not create an approved BPC-157 product, and did not approve it for any indication.
What would have to happen for this to change
- 1FDA completes its own evaluation. The advisory vote is non-binding — FDA can accept or reject it.
- 2FDA publishes a proposed rule in the Federal Register identifying substances proposed for inclusion or exclusion, with its reasoning.
- 3A public comment period opens. Anyone may submit evidence and scientific or legal objections.
- 4FDA reviews the comments and the administrative record.
- 5FDA publishes a final rule, or withdraws or modifies the proposal.
- 6The final rule takes effect and amends the list at 21 CFR 216.23.
Sources
- FDA briefing document (BPC-157)
- FDA meeting materials
- AP coverage of the vote
- RAPS, day one
- USADA on BPC-157
- 21 CFR 216.23
See the status of all seven peptides side by side in the FDA 503A compounding tracker. Or read our full guide to BPC-157.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.